CN110382464A - 烃基磺酰基取代的吡啶和其在癌症治疗中的用途 - Google Patents

烃基磺酰基取代的吡啶和其在癌症治疗中的用途 Download PDF

Info

Publication number
CN110382464A
CN110382464A CN201880010169.1A CN201880010169A CN110382464A CN 110382464 A CN110382464 A CN 110382464A CN 201880010169 A CN201880010169 A CN 201880010169A CN 110382464 A CN110382464 A CN 110382464A
Authority
CN
China
Prior art keywords
optionally
alkyl
cancer
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880010169.1A
Other languages
English (en)
Chinese (zh)
Inventor
B·佩尔克曼
E·苏纳
W·斯塔福德
M·普列德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obi Reek Treatment Co
Original Assignee
Obi Reek Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obi Reek Treatment Co filed Critical Obi Reek Treatment Co
Publication of CN110382464A publication Critical patent/CN110382464A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880010169.1A 2017-02-07 2018-02-07 烃基磺酰基取代的吡啶和其在癌症治疗中的用途 Pending CN110382464A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762455641P 2017-02-07 2017-02-07
US62/455,641 2017-02-07
US201762594794P 2017-12-05 2017-12-05
US62/594,794 2017-12-05
PCT/GB2018/050346 WO2018146472A1 (en) 2017-02-07 2018-02-07 Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer

Publications (1)

Publication Number Publication Date
CN110382464A true CN110382464A (zh) 2019-10-25

Family

ID=61274298

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880010169.1A Pending CN110382464A (zh) 2017-02-07 2018-02-07 烃基磺酰基取代的吡啶和其在癌症治疗中的用途

Country Status (13)

Country Link
US (2) US11161815B2 (https=)
EP (1) EP3580203A1 (https=)
JP (1) JP7229176B2 (https=)
KR (1) KR20190115014A (https=)
CN (1) CN110382464A (https=)
AU (1) AU2018218522B2 (https=)
BR (1) BR112019016248A2 (https=)
CA (1) CA3051539A1 (https=)
MA (1) MA47458A (https=)
MX (1) MX392900B (https=)
RU (1) RU2019128063A (https=)
WO (1) WO2018146472A1 (https=)
ZA (1) ZA201904966B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
AU2018218519B2 (en) 2017-02-07 2021-08-05 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
MA47450A (fr) 2017-02-07 2019-12-18 Oblique Therapeutics Ab Sulfinylpyridines et leur utilisation dans le traitement du cancer
CA3051539A1 (en) * 2017-02-07 2018-08-16 Oblique Therapeutics Ab Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
US11168069B2 (en) 2017-02-07 2021-11-09 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
EP3752151A1 (en) * 2018-02-12 2020-12-23 Cinda Pharma AB Thioredoxin reductase inhibitors for use in the treatment of cancer
EP4201929B1 (en) * 2021-12-24 2024-08-14 geneXplain GmbH Quinoxaline thioredoxin reductase inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272533A2 (de) * 1986-12-22 1988-06-29 Bayer Ag Substituierte Phenoxypyridine
DE19531148A1 (de) * 1995-08-24 1997-02-27 Basf Ag Fungizide Pyridin-2-yl-Derivate
WO2003093250A2 (en) * 2002-05-03 2003-11-13 Pharmacia & Upjohn Company Positive allosteric modulators of the nicotinic acetylcholine receptor
US20060019967A1 (en) * 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
WO2010007756A1 (ja) * 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
CN101723932A (zh) * 2008-10-31 2010-06-09 北京以岭生物工程有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
CN108026044A (zh) * 2015-08-07 2018-05-11 E·S·J·阿内尔 吡啶和其在癌症治疗中的用途
CN110382465A (zh) * 2017-02-07 2019-10-25 欧比力克治疗公司 亚磺酰基吡啶和其在癌症治疗中的用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3064846D1 (en) 1979-12-19 1983-10-20 Duphar Int Res New nitrothiophenes, method of preparing the new compounds, as well as fungicidal and/or bactericidal compositions on the basis of the new compounds
US4456469A (en) 1980-03-07 1984-06-26 E. I. Du Pont De Nemours And Company Pyridyl sulfone herbicides
AU543161B2 (en) 1980-03-07 1985-04-04 E.I. Du Pont De Nemours And Company Pyrimidine or s.triazine derivatives
US4791127A (en) 1985-10-07 1988-12-13 Nippon Kayaku Kabushiki Kaisha Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides
JPS63166865A (ja) * 1986-12-22 1988-07-11 バイエル・アクチエンゲゼルシヤフト 置換されたフエノキシピリジン類
DE3812177A1 (de) 1988-04-13 1989-10-26 Bayer Ag 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
US6069144A (en) * 1995-08-24 2000-05-30 Basf Aktiengesellschaft N-heterocyclic compounds, intermediate products used to prepare them, agents containing them and their use in antifungal applications
DE19531348A1 (de) 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo
US6191280B1 (en) 1997-05-30 2001-02-20 Basf Aktiengesellschaft Method for producing substituted thiopyridines
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
WO1999018096A1 (en) 1997-10-02 1999-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6191170B1 (en) 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
SI0930302T1 (en) 1998-01-16 2003-10-31 F. Hoffmann-La Roche Ag Benzosulfone derivatives
AU2001250783A1 (en) 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003068744A1 (en) 2002-02-18 2003-08-21 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
EA011671B1 (ru) 2004-06-04 2009-04-28 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
WO2007076875A2 (en) 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
CA2647338A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors-3
EP2061472A4 (en) * 2006-05-22 2010-12-22 Thioredoxin Systems Ab BACTERIAL THIOREDOXINE REDUCTASE INHIBITORS AND METHODS OF USING THE SAME
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
WO2010138820A2 (en) 2009-05-28 2010-12-02 President And Fellows Of Harvard College N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
KR101906146B1 (ko) 2009-08-17 2018-10-10 메모리얼 슬로안-케터링 캔서 센터 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
JP5850321B2 (ja) 2010-02-10 2016-02-03 公立大学法人横浜市立大学 神経選択的転写抑制因子ＮＲＳＦに特異的に結合するｍＳｉｎ３Ｂに結合する化合物の利用
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
WO2012025638A1 (en) 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
US9539256B2 (en) 2012-02-10 2017-01-10 The Board Of Regents Of The University Of Texas System Modulators of exchange proteins directly activated by cAMP (EPACS)
WO2015006458A1 (en) 2013-07-10 2015-01-15 Boehringer Ingelheim International Gmbh Novel chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes
CN104672214B (zh) 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
CN105503827B (zh) 2014-10-11 2019-09-24 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备方法和用途
CN104672241B (zh) 2015-01-29 2018-04-24 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
CN104987324B (zh) 2015-06-04 2018-05-04 湖北生物医药产业技术研究院有限公司 作为alk抑制剂的嘧啶衍生物
CN105085483B (zh) 2015-06-04 2019-01-01 湖北生物医药产业技术研究院有限公司 激酶抑制剂及其应用
US11168069B2 (en) 2017-02-07 2021-11-09 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
CA3051539A1 (en) * 2017-02-07 2018-08-16 Oblique Therapeutics Ab Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
AU2018218519B2 (en) 2017-02-07 2021-08-05 Oblique Therapeutics Ab Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272533A2 (de) * 1986-12-22 1988-06-29 Bayer Ag Substituierte Phenoxypyridine
DE19531148A1 (de) * 1995-08-24 1997-02-27 Basf Ag Fungizide Pyridin-2-yl-Derivate
WO2003093250A2 (en) * 2002-05-03 2003-11-13 Pharmacia & Upjohn Company Positive allosteric modulators of the nicotinic acetylcholine receptor
US20060019967A1 (en) * 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
WO2010007756A1 (ja) * 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
CN101723932A (zh) * 2008-10-31 2010-06-09 北京以岭生物工程有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
CN108026044A (zh) * 2015-08-07 2018-05-11 E·S·J·阿内尔 吡啶和其在癌症治疗中的用途
CN110382465A (zh) * 2017-02-07 2019-10-25 欧比力克治疗公司 亚磺酰基吡啶和其在癌症治疗中的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY: "RN246020-68-8" *

Also Published As

Publication number Publication date
BR112019016248A2 (pt) 2020-04-14
WO2018146472A1 (en) 2018-08-16
US20220119348A1 (en) 2022-04-21
AU2018218522A1 (en) 2019-08-15
MX2019009266A (es) 2019-11-05
MX392900B (es) 2025-03-24
US11161815B2 (en) 2021-11-02
MA47458A (fr) 2019-12-18
RU2019128063A3 (https=) 2021-05-21
CA3051539A1 (en) 2018-08-16
AU2018218522B2 (en) 2021-08-05
EP3580203A1 (en) 2019-12-18
KR20190115014A (ko) 2019-10-10
RU2019128063A (ru) 2021-03-09
JP2020506970A (ja) 2020-03-05
JP7229176B2 (ja) 2023-02-27
ZA201904966B (en) 2023-12-20
US20200239417A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
CN110382464A (zh) 烃基磺酰基取代的吡啶和其在癌症治疗中的用途
AU2022235580B2 (en) (AZA)indole-, benzothiophene-, and benzofuran-3-sulfonamides
KR102194646B1 (ko) 암 치료를 위한 피리미딘-2,4-다이아민 유도체
JP5335932B2 (ja) 制癌剤である二置換ピリジン誘導体
KR102180934B1 (ko) 피리딘 및 암의 치료에서의 이의 용도
US11168069B2 (en) Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
CN119053603A (zh) 一种含氮三稠环prmt5抑制剂，其制备方法和药学上的用途
CN110382465A (zh) 亚磺酰基吡啶和其在癌症治疗中的用途
CN110382486A (zh) 杂芳磺酰基取代的吡啶和其在癌症治疗中的用途
WO2013182451A9 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CN119013275A (zh) 一种prmt5抑制剂，其制备方法和在药学上的应用
RU2736501C2 (ru) Трициклические соединения и их применение для лечения рака
RU2777596C2 (ru) Гетероциклилсульфонил-замещенные пиридины и их применение при лечении рака
CN116891462A (zh) 一种山荷叶素衍生物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20191025